author-photo

Manisha Lamba

Bristol-Myers Squibb

5

Papers

22

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Pharmacodynamic (PD) responses drive dose/schedule selection of CC-92480, a novel CELMoD agent, in a phase 1 dose-escalation study in relapsed/refractory multiple myeloma (RRMM).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma

2020 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Phase I Study of Lysine-Specific Demethylase-1 Inhibitor CC-90011 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)